Alimera Sciences (ALIM) Misses Q3 EPS by 3c, Miss on Revenues

Alimera Sciences (NASDAQ: ALIM) reported Q3 EPS of ($0.08), $0.03 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $10.68 million.

• Net Revenue of $9.8 million for the third quarter of 2017 compared to $8.3 million for the third quarter of 2016, an 18% increase
• GAAP Net Loss of $5.3 million for the third quarter of 2017 compared to $9.2 million for the third quarter of 2016, a decrease of 42%
• Adjusted EBITDA Loss of $1.8 million for the third quarter of 2017 compared to $5.4 million for the third quarter of 2016, a decrease of 67%
  

For earnings history and earnings-related data on Alimera Sciences (ALIM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c